COVID-19和ARDS患者肝素和直接凝血酶抑制剂体外膜氧合期间抗凝血药物的使用

Q2 Health Professions
Alfred H Stammers, Eric A Tesdahl, Shannon Barletti, Linda Mongero, Kirti Patel, Matthew Mosca, Anthony Sestokas, Michael S Firstenberg, Jeffrey P Jacobs
{"title":"COVID-19和ARDS患者肝素和直接凝血酶抑制剂体外膜氧合期间抗凝血药物的使用","authors":"Alfred H Stammers,&nbsp;Eric A Tesdahl,&nbsp;Shannon Barletti,&nbsp;Linda Mongero,&nbsp;Kirti Patel,&nbsp;Matthew Mosca,&nbsp;Anthony Sestokas,&nbsp;Michael S Firstenberg,&nbsp;Jeffrey P Jacobs","doi":"10.1182/ject-223-234","DOIUrl":null,"url":null,"abstract":"<p><p>Coagulopathies develop in patients supported with the use of extracorporeal membrane oxygenation (ECMO) and can be hemorrhagic and/or thrombophilic in spite of the use of systemic anticoagulation. The purpose this study was to examine the use of heparin and direct thrombin inhibitors (DTI) in COVID-19 patients with acute respiratory distress syndrome (ARDS) on ECMO, with a subset analysis by disease state. Following IRB approval, 570 consecutive records were reviewed of adult patients on venovenous ECMO between May 2020 and December 2021. Patients were grouped by anticoagulant use: Heparin Only (n = 373), DTI Only (bivalirudin or argatroban, n = 90), or DTI after Heparin (n = 107). The effect of anticoagulant grouping was assessed using Bayesian mixed-effects logistic regression adjusting for age, body mass index (BMI), gender, days of mechanical ventilation prior to ECMO, indication for ECMO support, hepatic and renal failure, hours on ECMO, hours off anticoagulation, coagulation monitoring target, and hospital. The primary endpoint was circuit failure requiring change-out with secondary endpoints of organ failure and mortality. Regression-adjusted probability of circuit change-outs were as follows: DTI after Heparin patients-32.7%, 95% Credible Interval [16.1-51.9%]; DTI Only patients-23.3% [7.5-40.8%]; and Heparin Only patients-19.8% [8.1-31.3%]. The posterior probability of difference between groups was strongest for DTI after Heparin vs. Heparin Only (97.0%), moderate for DTI after Heparin vs. DTI Only (88.2%), and weak for DTI Only vs. Heparin only (66.6%). The occurrence of both hepatic and renal failure for DTI Only and DTI after Heparin patients was higher than that of Heparin Only patients. Unadjusted mortality was highest for DTI after Heparin (64.5%) followed by DTI Only (56.7%), and Heparin Only (50.1%, <i>p</i> = 0.027). DTI after Heparin was associated with an increased likelihood of circuit change-out. Unadjusted hepatic failure, renal failure, and mortality were more frequent among DTI patients than Heparin Only patients.</p>","PeriodicalId":39644,"journal":{"name":"Journal of Extra-Corporeal Technology","volume":"54 3","pages":"223-234"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891485/pdf/ject-223-234.pdf","citationCount":"1","resultStr":"{\"title\":\"Anticoagulant Use During Extracorporeal Membrane Oxygenation Using Heparin and Direct Thrombin Inhibitors in COVID-19 and ARDS Patients.\",\"authors\":\"Alfred H Stammers,&nbsp;Eric A Tesdahl,&nbsp;Shannon Barletti,&nbsp;Linda Mongero,&nbsp;Kirti Patel,&nbsp;Matthew Mosca,&nbsp;Anthony Sestokas,&nbsp;Michael S Firstenberg,&nbsp;Jeffrey P Jacobs\",\"doi\":\"10.1182/ject-223-234\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Coagulopathies develop in patients supported with the use of extracorporeal membrane oxygenation (ECMO) and can be hemorrhagic and/or thrombophilic in spite of the use of systemic anticoagulation. The purpose this study was to examine the use of heparin and direct thrombin inhibitors (DTI) in COVID-19 patients with acute respiratory distress syndrome (ARDS) on ECMO, with a subset analysis by disease state. Following IRB approval, 570 consecutive records were reviewed of adult patients on venovenous ECMO between May 2020 and December 2021. Patients were grouped by anticoagulant use: Heparin Only (n = 373), DTI Only (bivalirudin or argatroban, n = 90), or DTI after Heparin (n = 107). The effect of anticoagulant grouping was assessed using Bayesian mixed-effects logistic regression adjusting for age, body mass index (BMI), gender, days of mechanical ventilation prior to ECMO, indication for ECMO support, hepatic and renal failure, hours on ECMO, hours off anticoagulation, coagulation monitoring target, and hospital. The primary endpoint was circuit failure requiring change-out with secondary endpoints of organ failure and mortality. Regression-adjusted probability of circuit change-outs were as follows: DTI after Heparin patients-32.7%, 95% Credible Interval [16.1-51.9%]; DTI Only patients-23.3% [7.5-40.8%]; and Heparin Only patients-19.8% [8.1-31.3%]. The posterior probability of difference between groups was strongest for DTI after Heparin vs. Heparin Only (97.0%), moderate for DTI after Heparin vs. DTI Only (88.2%), and weak for DTI Only vs. Heparin only (66.6%). The occurrence of both hepatic and renal failure for DTI Only and DTI after Heparin patients was higher than that of Heparin Only patients. Unadjusted mortality was highest for DTI after Heparin (64.5%) followed by DTI Only (56.7%), and Heparin Only (50.1%, <i>p</i> = 0.027). DTI after Heparin was associated with an increased likelihood of circuit change-out. Unadjusted hepatic failure, renal failure, and mortality were more frequent among DTI patients than Heparin Only patients.</p>\",\"PeriodicalId\":39644,\"journal\":{\"name\":\"Journal of Extra-Corporeal Technology\",\"volume\":\"54 3\",\"pages\":\"223-234\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891485/pdf/ject-223-234.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Extra-Corporeal Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1182/ject-223-234\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Health Professions\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Extra-Corporeal Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1182/ject-223-234","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 1

摘要

凝血功能障碍在使用体外膜氧合(ECMO)支持的患者中发展,尽管使用全身抗凝,但可能出现出血和/或血栓形成。本研究的目的是研究肝素和直接凝血酶抑制剂(DTI)在COVID-19急性呼吸窘迫综合征(ARDS)患者ECMO中的使用情况,并按疾病状态进行亚群分析。在IRB批准后,在2020年5月至2021年12月期间审查了570例静脉-静脉ECMO成人患者的连续记录。患者按抗凝剂使用情况分组:仅使用肝素(n = 373),仅使用DTI(比伐鲁定或阿加曲班,n = 90),或肝素后使用DTI (n = 107)。采用贝叶斯混合效应logistic回归对年龄、体重指数(BMI)、性别、ECMO前机械通气天数、ECMO支持指征、肝肾衰竭、ECMO使用时间、停用抗凝时间、凝血监测指标和医院进行校正,评估抗凝分组的效果。主要终点是需要更换的电路衰竭,次要终点是器官衰竭和死亡率。经回归校正后电路改变的概率如下:肝素患者术后DTI -32.7%, 95%可信区间[16.1-51.9%];仅DTI患者-23.3% [7.5-40.8%];仅使用肝素的患者-19.8%[8.1-31.3%]。组间后验概率差异中,肝素组与单纯肝素组的后验概率差异最大(97.0%),肝素组与单纯肝素组的后验概率差异中等(88.2%),单纯肝素组与单纯肝素组的后验概率差异较小(66.6%)。单用DTI和肝素治疗后DTI患者的肝肾功能衰竭发生率均高于单用肝素治疗组。肝素治疗后DTI的未调整死亡率最高(64.5%),其次是DTI(56.7%)和肝素治疗(50.1%,p = 0.027)。肝素后的DTI与电路改变的可能性增加有关。在DTI患者中,未调整的肝功能衰竭、肾功能衰竭和死亡率比仅使用肝素的患者更常见。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Anticoagulant Use During Extracorporeal Membrane Oxygenation Using Heparin and Direct Thrombin Inhibitors in COVID-19 and ARDS Patients.

Coagulopathies develop in patients supported with the use of extracorporeal membrane oxygenation (ECMO) and can be hemorrhagic and/or thrombophilic in spite of the use of systemic anticoagulation. The purpose this study was to examine the use of heparin and direct thrombin inhibitors (DTI) in COVID-19 patients with acute respiratory distress syndrome (ARDS) on ECMO, with a subset analysis by disease state. Following IRB approval, 570 consecutive records were reviewed of adult patients on venovenous ECMO between May 2020 and December 2021. Patients were grouped by anticoagulant use: Heparin Only (n = 373), DTI Only (bivalirudin or argatroban, n = 90), or DTI after Heparin (n = 107). The effect of anticoagulant grouping was assessed using Bayesian mixed-effects logistic regression adjusting for age, body mass index (BMI), gender, days of mechanical ventilation prior to ECMO, indication for ECMO support, hepatic and renal failure, hours on ECMO, hours off anticoagulation, coagulation monitoring target, and hospital. The primary endpoint was circuit failure requiring change-out with secondary endpoints of organ failure and mortality. Regression-adjusted probability of circuit change-outs were as follows: DTI after Heparin patients-32.7%, 95% Credible Interval [16.1-51.9%]; DTI Only patients-23.3% [7.5-40.8%]; and Heparin Only patients-19.8% [8.1-31.3%]. The posterior probability of difference between groups was strongest for DTI after Heparin vs. Heparin Only (97.0%), moderate for DTI after Heparin vs. DTI Only (88.2%), and weak for DTI Only vs. Heparin only (66.6%). The occurrence of both hepatic and renal failure for DTI Only and DTI after Heparin patients was higher than that of Heparin Only patients. Unadjusted mortality was highest for DTI after Heparin (64.5%) followed by DTI Only (56.7%), and Heparin Only (50.1%, p = 0.027). DTI after Heparin was associated with an increased likelihood of circuit change-out. Unadjusted hepatic failure, renal failure, and mortality were more frequent among DTI patients than Heparin Only patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Extra-Corporeal Technology
Journal of Extra-Corporeal Technology Medicine-Medicine (all)
CiteScore
1.90
自引率
0.00%
发文量
12
期刊介绍: The Journal of Extracorporeal Technology is dedicated to the study and practice of Basic Science and Clinical issues related to extracorporeal circulation. Areas emphasized in the Journal include: •Cardiopulmonary Bypass •Cardiac Surgery •Cardiovascular Anesthesia •Hematology •Blood Management •Physiology •Fluid Dynamics •Laboratory Science •Coagulation and Hematology •Transfusion •Business Practices •Pediatric Perfusion •Total Quality Management • Evidence-Based Practices
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信